- Home
- PGRE vs MLYS Comparison
PGRE vs MLYS Comparison
Compare PGRE & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGRE
- MLYS
- Stock Information
- Founded
- PGRE 1978
- MLYS 2019
- Country
- PGRE United States
- MLYS United States
- Employees
- PGRE N/A
- MLYS N/A
- Industry
- PGRE Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- PGRE Real Estate
- MLYS Health Care
- Exchange
- PGRE Nasdaq
- MLYS Nasdaq
- Market Cap
- PGRE 953.6M
- MLYS 893.0M
- IPO Year
- PGRE 2014
- MLYS 2023
- Fundamental
- Price
- PGRE $4.56
- MLYS $14.65
- Analyst Decision
- PGRE Hold
- MLYS Strong Buy
- Analyst Count
- PGRE 3
- MLYS 3
- Target Price
- PGRE $4.33
- MLYS $33.00
- AVG Volume (30 Days)
- PGRE 2.6M
- MLYS 650.3K
- Earning Date
- PGRE 04-30-2025
- MLYS 05-12-2025
- Dividend Yield
- PGRE 0.77%
- MLYS N/A
- EPS Growth
- PGRE N/A
- MLYS N/A
- EPS
- PGRE N/A
- MLYS N/A
- Revenue
- PGRE $711,729,000.00
- MLYS N/A
- Revenue This Year
- PGRE $1.17
- MLYS N/A
- Revenue Next Year
- PGRE N/A
- MLYS N/A
- P/E Ratio
- PGRE N/A
- MLYS N/A
- Revenue Growth
- PGRE 49.28
- MLYS N/A
- 52 Week Low
- PGRE $3.75
- MLYS $8.24
- 52 Week High
- PGRE $5.47
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- PGRE 56.45
- MLYS 53.36
- Support Level
- PGRE $4.50
- MLYS $14.03
- Resistance Level
- PGRE $4.79
- MLYS $15.79
- Average True Range (ATR)
- PGRE 0.16
- MLYS 0.99
- MACD
- PGRE 0.03
- MLYS 0.10
- Stochastic Oscillator
- PGRE 66.19
- MLYS 57.57
About PGRE Paramount Group Inc.
Paramount Group Inc is a real estate investment trust engaged in owning, operating, managing, acquiring, and redeveloping high-quality, Class A office properties in select central business district (CBD) submarkets of New York City and San Francisco. The company operates in two geographical segments New York and San Francisco. The company derives nearly all of its majority of revenue from rental income.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.